Selegiline and Methamphetamine in Rats: What Behavioral Tests and Receptor Blockade Can Show
Selegiline changed several behavioral measures in a rat experiment involving repeated methamphetamine administration. The useful question is what those changes establish about the experiment, rather than whether they demonstrate a treatment for human methamphetamine-related mood disorders.
What the experiment measured
Gholami and colleagues used male Wistar rats and a 21-day administration schedule. The reported methamphetamine dose was 10 mg/kg. The abstract describes selegiline groups receiving 10, 15 or 20 mg/kg alongside methamphetamine, with additional groups receiving haloperidol or trazodone before selegiline. Behavioral testing occurred on days 23 and 24.
The open-field test recorded ambulation, rearing, entries into the central area and time spent there. The elevated plus maze recorded entries and time in open and closed arms. These are observed rodent behaviors. Calling them anxiety-related measures does not turn them into clinical diagnoses of anxiety or depression.
Movement and exploration changed together
Compared with the control condition, methamphetamine was associated with less open-field movement and exploration and less time and fewer entries in open maze arms. The selegiline combinations shifted several measures toward the control pattern. The paper reports statistically significant differences for the examined comparisons.
Interpretation requires attention to movement as well as arm preference. When an intervention changes ambulation, a change in the number of open-arm entries may partly reflect the animal’s opportunity or ability to explore. The tests supply behavioral evidence, but they do not independently identify a single emotional mechanism.
What antagonist blockade adds
The investigators used haloperidol as a D2 receptor antagonist and trazodone as a 5-HT2 receptor antagonist. Pretreatment attenuated the behavioral effects attributed to selegiline. That pattern supports the authors’ proposal that these receptor systems may participate in the response under the experimental conditions.
It does not demonstrate exclusive receptor mediation. The article’s described groups do not establish independent effects of each antagonist under every relevant condition, and the experiment does not directly measure receptor occupancy or the complete downstream pathway. Behavioral attenuation after another drug is added is evidence for a mechanistic hypothesis, not a complete map of causation. The authors themselves call for molecular and cellular investigation.
Preserve the paper’s reporting inconsistencies
The abstract states that 70 rats were divided into eight groups of 10, while its numbered treatment descriptions run from Group 1 through Group 7. Those statements cannot all describe the same total without additional clarification. It is inappropriate to silently replace the reported denominator with an assumed corrected number.
The discussion also contains a dose sequence that differs from the 10, 15 and 20 mg/kg sequence described in the abstract. A careful summary can report the abstract’s schedule while making clear that the article does not provide a uniformly consistent account. These discrepancies limit reconstruction of the experiment; they do not license invented treatment arms or animal counts.
How the findings apply to scientific review
The study concerns repeated experimentally administered exposure in rats and subsequent behavioral testing. It does not test human withdrawal treatment, driving performance, individual impairment or the origin of a laboratory methamphetamine result. Questions about selegiline as a metabolic source of a drug finding require different evidence from this behavioral experiment.
The supported conclusion is narrow: selegiline-associated changes and their attenuation by antagonist pretreatment identify a preclinical behavioral pattern worth investigating. They do not establish clinical efficacy, a human dosing strategy or proof that a particular receptor exclusively caused the observed behavior.
Scientific source
Gholami M, Kaviani N, Motaghinejad M, Ulloa L. Neuroprotective Effects of Selegiline Agent Methamphetamine-Prompted Mood-Related Behavior Disorder Mediated Via 5-HT2 and D2 Receptors. International Journal of Preventive Medicine. 2023;14:78. DOI: 10.4103/ijpvm.ijpvm_42_22. This analysis uses the supplied paper. The interpretation of its evidentiary limits is analysis of that report.



